Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...
Pharmaceutical Technology on MSN1d
WuXi XDC and AbTis collaborate on antibody-drug conjugatesThe partnership combines AbTis' AbClick site-selective conjugation platform with WuXi XDC's all-in-one development and ...
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global ...
Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...
Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...
In a precedential opinion issued on March 6, the Federal Circuit affirmed the US District Court for the Eastern District of Virginia that the ...
Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop ...
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback